scholarly article | Q13442814 |
P356 | DOI | 10.1007/S10637-015-0246-2 |
P8608 | Fatcat ID | release_uqq4h33smrgjdnrs6xu7wncwyy |
P932 | PMC publication ID | 4905857 |
P698 | PubMed publication ID | 25952464 |
P50 | author | Katrina S Pedersen | Q87264362 |
Charles Erlichman | Q107069384 | ||
P2093 | author name string | Robert R McWilliams | |
Nathan R Foster | |||
George P Kim | |||
Andrea Wang-Gillam | |||
P2860 | cites work | A pathway of multi-chaperone interactions common to diverse regulatory proteins: estrogen receptor, Fes tyrosine kinase, heat shock transcription factor Hsf1, and the aryl hydrocarbon receptor | Q24627720 |
Nonparametric Estimation from Incomplete Observations | Q25938997 | ||
Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma | Q28300339 | ||
Geldanamycin induces heat shock protein expression through activation of HSF1 in K562 erythroleukemic cells | Q28368209 | ||
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial | Q29547565 | ||
Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine | Q29616728 | ||
Steroid receptor interactions with heat shock protein and immunophilin chaperones | Q29619628 | ||
Phase I study of BIIB028, a selective heat shock protein 90 inhibitor, in patients with refractory metastatic or locally advanced solid tumors | Q33163062 | ||
Phase I study of 17-allylamino-17 demethoxygeldanamycin, gemcitabine and/or cisplatin in patients with refractory solid tumors | Q33387877 | ||
Targeting the molecular chaperone heat shock protein 90 (HSP90): lessons learned and future directions | Q34314706 | ||
A first in human, safety, pharmacokinetics, and clinical activity phase I study of once weekly administration of the Hsp90 inhibitor ganetespib (STA-9090) in patients with solid malignancies | Q34636437 | ||
Phase I and pharmacological study of cytarabine and tanespimycin in relapsed and refractory acute leukemia | Q35528633 | ||
The Stress Response: Implications for the Clinical Development of Hsp90 Inhibitors | Q35551875 | ||
A phase II study of gemcitabine in combination with tanespimycin in advanced epithelial ovarian and primary peritoneal carcinoma | Q35691439 | ||
Cisplatin abrogates the geldanamycin-induced heat shock response | Q36948038 | ||
Gemcitabine-induced activation of checkpoint signaling pathways that affect tumor cell survival. | Q40380713 | ||
The heat shock protein 90 inhibitor geldanamycin and the ErbB inhibitor ZD1839 promote rapid PP1 phosphatase-dependent inactivation of AKT in ErbB2 overexpressing breast cancer cells. | Q40614350 | ||
Hsp90 inhibition depletes Chk1 and sensitizes tumor cells to replication stress | Q40624388 | ||
Phosphorylated Akt/PKB controls cell growth and apoptosis in intraductal papillary-mucinous tumor and invasive ductal adenocarcinoma of the pancreas | Q40661394 | ||
Geldanamycin restores a defective heat shock response in vivo | Q40778294 | ||
Depletion of p185erbB2, Raf-1 and mutant p53 proteins by geldanamycin derivatives correlates with antiproliferative activity | Q41139893 | ||
Induction of a heat shock factor 1-dependent stress response alters the cytotoxic activity of hsp90-binding agents. | Q42492406 | ||
First-in-human phase I dose-escalation study of the HSP90 inhibitor AUY922 in patients with advanced solid tumors | Q44893938 | ||
Frequent activation of AKT2 kinase in human pancreatic carcinomas | Q47251291 | ||
Inhibition of the oncogene product p185erbB-2 in vitro and in vivo by geldanamycin and dihydrogeldanamycin derivatives | Q71751283 | ||
Tanespimycin pharmacokinetics: a randomized dose-escalation crossover phase 1 study of two formulations | Q84587884 | ||
P433 | issue | 4 | |
P921 | main subject | tanespimycin | Q4552288 |
pancreatic cancer | Q212961 | ||
phase II clinical trial | Q42824440 | ||
P304 | page(s) | 963-968 | |
P577 | publication date | 2015-05-08 | |
P1433 | published in | Investigational New Drugs | Q2312231 |
P1476 | title | Phase II trial of gemcitabine and tanespimycin (17AAG) in metastatic pancreatic cancer: a Mayo Clinic Phase II Consortium study | |
P478 | volume | 33 |
Q41197997 | 17AAG-induced internalisation of HER2-specific Affibody molecules |
Q92358243 | A Long Non-coding RNA Lnc712 Regulates Breast Cancer Cell Proliferation |
Q92404317 | Heat Shock Protein 90 as a Prognostic Marker and Therapeutic Target for Adrenocortical Carcinoma |
Q28075606 | Mantle cell lymphoma in the era of precision medicine-diagnosis, biomarkers and therapeutic agents |
Q90293459 | Novel insights into molecular chaperone regulation of ribonucleotide reductase |
Q38648236 | Realistic biological approaches for improving thermoradiotherapy. |
Q52655041 | Sensitization of multidrug-resistant cancer cells to Hsp90 inhibitors by NSAIDs-induced apoptotic and autophagic cell death. |
Q33688577 | Small molecule inhibitor screening identifified HSP90 inhibitor 17-AAG as potential therapeutic agent for gallbladder cancer. |
Q42317467 | TNF induced cleavage of HSP90 by cathepsin D potentiates apoptotic cell death |
Q52716432 | Targeting the Hsp90-Cdc37-client protein interaction to disrupt Hsp90 chaperone machinery. |
Q92463715 | The challenge of drug resistance in pancreatic ductal adenocarcinoma: a current overview |
Search more.